Since ATLL is thought to originate primarily from CD4 T cells, we posit that IGF1R, KDR (VEGFR), and FGFR1 may serve as potential therapeutic targets for future treatments of ATLL. This evidence concerns the gene KDR and adult T-cell leukemia/lymphoma.